Chronic Heart Failure – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of chronic heart failure (CHF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea, and Turkey). We report the prevalence of CHF for each country, as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 10 years for the emerging pharmaceutical markets covered in this report.

Clarivate Epidemiology’s CHF forecast will answer the following questions:

• Of all people with CHF, how many in each country have been formally diagnosed?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CHF over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides 10 years of forecast data for the following CHF subpopulations:

• Diagnosed prevalent CHF cases by New York Heart Association (NYHA) functional classification status.
• Diagnosed prevalent cases of CHF characterized by reduced ejection fraction (EF).
• Diagnosed prevalent cases of CHF characterized by preserved or mid-range EF.

… and more (details available on request).

Note: Coverage may vary by country.